Ivarmacitinib
- Generic Name
- Ivarmacitinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H22N8O2S
- CAS Number
- 1445987-21-2
- Unique Ingredient Identifier
- K6K4B9Z5TV
- Background
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis, ankylosing spondylitis, rheumatoid arthr...
- Associated Conditions
- -
- Associated Therapies
- -
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT06731153
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath